KalVista Pharmaceuticals, Inc.‘s proposed name “sebetralstat” has been approved by the World Health Organization’s International Nonproprietary Names (WHO-INN) Expert Committee and the American Medical Association’s United States Adopted Names (AMA-USAN) Council for the drug candidate formerly known as KVD900. Sebetralstat is currently being evaluated in the Phase 3 KONFIDENT study as a potential therapeutic for on-demand treatment of HAE attacks.
“We are excited to announce this next important step in the evolution of sebetralstat as the first potential oral on-demand therapeutic for HAE,” says Andrew Crockett, CEO of KalVista. “The KONFIDENT study continues to enroll on track with our expectations, and we have many other activities ongoing to prepare for the eventual NDA submission. We believe sebetralstat can be a transformational therapy for people living with HAE.”
(Source: KalVista)
